Wedbush Issues Negative Outlook for Kura Oncology Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Wedbush dropped their Q1 2025 earnings estimates for shares of Kura Oncology in a research note issued to investors on Thursday, February 27th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.87) for the quarter, down from their previous forecast of ($0.70). Wedbush currently has a “Outperform” rating and a $36.00 price target on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Wedbush also issued estimates for Kura Oncology’s Q2 2025 earnings at ($0.95) EPS, Q3 2025 earnings at $1.36 EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($4.08) EPS and FY2028 earnings at ($1.33) EPS.

KURA has been the subject of several other research reports. Bank of America cut their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. StockNews.com raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, February 27th. Finally, JMP Securities reissued a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Price Performance

NASDAQ:KURA opened at $7.25 on Monday. The company has a 50 day moving average price of $8.14 and a 200-day moving average price of $13.73. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The firm has a market cap of $563.79 million, a price-to-earnings ratio of -3.07 and a beta of 0.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million.

Insiders Place Their Bets

In related news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 over the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

Institutional investors have recently bought and sold shares of the business. Barclays PLC increased its stake in Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after purchasing an additional 84,563 shares during the last quarter. SG Americas Securities LLC purchased a new position in Kura Oncology during the 4th quarter worth approximately $436,000. Moody Aldrich Partners LLC grew its position in shares of Kura Oncology by 42.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after acquiring an additional 42,712 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after buying an additional 2,076 shares during the period. Finally, Jennison Associates LLC acquired a new position in shares of Kura Oncology in the fourth quarter valued at approximately $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.